{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:40:12Z","timestamp":1776919212653,"version":"3.51.2"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.jpba.2010.03.004","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T05:08:31Z","timestamp":1268111311000},"page":"734-740","source":"Crossref","is-referenced-by-count":36,"title":["Analytical issues in HPLC\/MS\/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples"],"prefix":"10.1016","volume":"52","author":[{"given":"Daniela Iuliana","family":"Sora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015etefan","family":"Udrescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florin","family":"Albu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Medvedovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2010.03.004_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jpba.2008.07.003","article-title":"Recent developments in analytical determination of furosemide","volume":"48","author":"Espinosa Bosch","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2010.03.004_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0731-7085(95)01652-X","article-title":"Comparison of two extraction methods for determination of propranolol and furosemide in human plasma by mixed-mode chromatography","volume":"14","author":"Walshe","year":"1996","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2010.03.004_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0378-4347(97)00055-8","article-title":"Determination of pharmaco-kinetics of furosemide\u2013amiloride drug combination","volume":"693","author":"Jankowski","year":"1997","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2010.03.004_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4067\/S0717-97072005000200008","article-title":"Method validation for the determination of furosemide in plasma by liquid\u2013liquid extraction and high-performance liquid chromatography with fluorescence detection","volume":"50","author":"Gomez","year":"2005","journal-title":"J. Chilean Chem. Soc."},{"key":"10.1016\/j.jpba.2010.03.004_bib5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jpba.2006.02.025","article-title":"Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography","volume":"41","author":"Wenk","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2010.03.004_bib6","first-page":"416","article-title":"Quantitative determination of furosemide in human plasma by LC\/MS\/MS","volume":"11-S1","author":"Vallee","year":"1999","journal-title":"AAPS Pharm. Sci. J."},{"key":"10.1016\/j.jpba.2010.03.004_bib7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0014-827X(00)00064-1","article-title":"High-performance liquid chromatography\u2013mass spectrometric analysis of furosemide in plasma and its use in pharmacokinetic studies","volume":"55","author":"Abdel-Hamid","year":"2000","journal-title":"Farmaco"},{"key":"10.1016\/j.jpba.2010.03.004_bib8","first-page":"115","article-title":"Sample preparation and RPHPLC determination of diuretics in human body fluids","volume":"56","author":"Zendelovska","year":"2006","journal-title":"Acta Pharm."},{"key":"10.1016\/j.jpba.2010.03.004_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/jms.1006","article-title":"Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC\u2013APCI\u2013MS","volume":"41","author":"Dong","year":"2006","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2010.03.004_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchromb.2006.02.017","article-title":"Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples","volume":"839","author":"Sandall","year":"2006","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2010.03.004_bib11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1185\/03007999109111516","article-title":"Bioequivalence between two furosemide\u2013spironolactone formulations: a pharmacokinetic and pharmacodynamic approach","volume":"12","author":"Sch\u00fctz","year":"1991","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jpba.2010.03.004_bib12","first-page":"231","article-title":"Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide","volume":"36","author":"Vergin","year":"1998","journal-title":"Int. J. Clin Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2010.03.004_bib13","first-page":"275","article-title":"Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects","volume":"36","author":"Abou-Auda","year":"1998","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2010.03.004_bib14","first-page":"321","article-title":"In vivo pharmacokinetic\u2013pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations","volume":"53","author":"Cuadrado","year":"2003","journal-title":"Arzneim. Forsch."},{"key":"10.1016\/j.jpba.2010.03.004_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/bdd.361","article-title":"Bioequivalence evaluation of two brands of furosemide 40mg tablets (Salurin and Lasix) in healthy human volunteers","volume":"24","author":"Najib","year":"2003","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.jpba.2010.03.004_bib16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.5414\/CPP46527","article-title":"Evaluating average bioequivalence using methods for high variability drugs: a case study","volume":"46","author":"Sanchez","year":"2008","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2010.03.004_bib17","first-page":"117","article-title":"Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers","volume":"58","author":"Xu","year":"2008","journal-title":"Arzneim. Forsch."},{"key":"10.1016\/j.jpba.2010.03.004_bib18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/bmc.1152","article-title":"Dodging matrix effects in liquid chromatography tandem mass spectrometric assays-compilation of key learnings and perspectives","volume":"23","author":"Srinivas","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2010.03.004_bib19","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/ac971078+","article-title":"C.M. Chavez-Eng, matrix effect in quantitative LC\/MS\/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations","volume":"70","author":"Matuszewski","year":"1998","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2010.03.004_bib20","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC\u2013MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2010.03.004_bib21","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/rcm.1139","article-title":"Matrix effects during analysis of plasma samples by electrospray and atmospheric pressure chemical ionization mass spectrometry: practical approaches to their elimination","volume":"17","author":"Schuhmache","year":"2003","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2010.03.004_bib22","unstructured":"ICH topic Q2B, Note for guidance on validation of analytical procedures: methodology, (CPMP\/ICH\/281\/95), ICH Technical Coordination, London, UK, 1996."},{"key":"10.1016\/j.jpba.2010.03.004_bib23","unstructured":"ICH topic Q2R1, Note for guidance on validation of analytical procedures: text and methodology, (CPMP\/ICH\/381\/95), ICH Technical Coordination, London, UK, 1996."},{"key":"10.1016\/j.jpba.2010.03.004_bib24","series-title":"Statistical Theory and Methodology of Trace Analysis, Chapter 6 \u2014 Detection Theory of Analytical Signals","author":"Liteanu","year":"1980"},{"key":"10.1016\/j.jpba.2010.03.004_bib25","unstructured":"Guidance for Industry, Bioanalytical Method Validation. U.S. Department of Health and Human Services, FDA, CDER, CVM, 2001."},{"key":"10.1016\/j.jpba.2010.03.004_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/bdd.2510060202","article-title":"Pharmacokinetics of furosemide after three different oral doses","volume":"6","author":"Waller","year":"2006","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.jpba.2010.03.004_bib27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/0091270003254575","article-title":"Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers","volume":"43","author":"Klauser","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2010.03.004_bib28","first-page":"381","article-title":"Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (part 1)","volume":"18","author":"Ponto","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2010.03.004_bib29","first-page":"460","article-title":"Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (part 2)","volume":"18","author":"Ponto","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2010.03.004_bib30","first-page":"210","article-title":"The bioavailability of two new preparations of spironolactone tablets","volume":"5","author":"Nijkerk","year":"1983","journal-title":"Pharm. World Sci."},{"key":"10.1016\/j.jpba.2010.03.004_bib31","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/ndt\/gfg388","article-title":"Safety of low-dose spironolactone administration in chronic haemodialysis patients","volume":"18","author":"Saudan","year":"2003","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708510001470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708510001470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T13:23:24Z","timestamp":1544621004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708510001470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0731708510001470"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2010.03.004","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}